Merck & Co., Inc. Payments for Restructuring
Merck & Co., Inc. (MRK) reported Payments for Restructuring of $63.00 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-02.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2025-05-02
- Merck & Co., Inc. payments for restructuring for the quarter ending 2025-03-31 was $63.00M, a 36.36% decline year-over-year.
- Merck & Co., Inc. payments for restructuring for the quarter ending 2024-12-31 was $146.00M, a 25.86% increase year-over-year.
- Merck & Co., Inc. payments for restructuring for the quarter ending 2024-09-30 was $94.00M, a 30.88% decline year-over-year.
- Merck & Co., Inc. payments for restructuring for the quarter ending 2024-06-30 was $106.00M, a 26.19% increase year-over-year.
- Merck & Co., Inc. payments for restructuring for fiscal 2024 was $445.00M, a 8.54% increase from fiscal 2023.
- Merck & Co., Inc. payments for restructuring for fiscal 2023 was $410.00M, a 8.69% decline from fiscal 2022.
- Merck & Co., Inc. payments for restructuring for fiscal 2022 was $449.00M, a 26.15% decline from fiscal 2021.
- Merck & Co., Inc. payments for restructuring for fiscal 2021 was $608.00M, a 21.95% decline from fiscal 2020.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month | Payments for Restructuring 12 month as first filed |
|---|---|---|---|---|---|
| 2025-03-31 | $63.00M 10-Q · filed 2025-05-02 | $209.00M derived: sum of 2 quarters · filed 2025-05-02 | $303.00M derived: sum of 3 quarters · filed 2025-05-02 | $409.00M derived: sum of 4 quarters · filed 2025-05-02 | |
| 2024-12-31 | $146.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $240.00M derived: sum of 2 quarters · filed 2025-02-25 | $346.00M derived: sum of 3 quarters · filed 2025-02-25 | $445.00M 10-K · filed 2025-02-25 | |
| 2024-09-30 | $94.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $200.00M derived: sum of 2 quarters · filed 2024-11-06 | $299.00M 10-Q · filed 2024-11-06 | $415.00M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2024-06-30 | $106.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $205.00M 10-Q · filed 2024-08-05 | $321.00M derived: sum of 3 quarters · filed 2025-02-25 | $457.00M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2024-03-31 | $99.00M 10-Q · filed 2024-05-03 | $215.00M derived: sum of 2 quarters · filed 2025-02-25 | $351.00M derived: sum of 3 quarters · filed 2025-02-25 | $435.00M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-12-31 | $116.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $252.00M derived: sum of 2 quarters · filed 2025-02-25 | $336.00M derived: sum of 3 quarters · filed 2025-02-25 | $410.00M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $136.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $220.00M derived: sum of 2 quarters · filed 2023-11-03 | $294.00M 10-Q · filed 2023-11-03 | -$18.00M derived: sum of 4 quarters · filed 2023-11-03 | |
| 2023-06-30 | $84.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $158.00M 10-Q · filed 2023-08-07 | -$154.00M derived: sum of 3 quarters · filed 2023-08-07 | $160.00M derived: sum of 4 quarters · filed 2023-08-07 | |
| 2023-03-31 | $74.00M 10-Q · filed 2023-05-05 | -$238.00M derived: sum of 2 quarters · filed 2023-05-05 | $76.00M derived: sum of 3 quarters · filed 2023-05-05 | $410.00M derived: sum of 4 quarters · filed 2023-05-05 | |
| 2022-12-31 | -$312.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $2.00M derived: sum of 2 quarters · filed 2023-02-24 | $336.00M derived: sum of 3 quarters · filed 2023-02-24 | $449.00M 10-K · filed 2023-02-24 | |
| 2022-09-30 | $314.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $648.00M derived: sum of 2 quarters · filed 2022-11-03 | $761.00M 10-Q · filed 2022-11-03 | $909.00M derived: sum of 4 quarters · filed 2023-02-24 | |
| 2022-06-30 | $334.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $447.00M 10-Q · filed 2022-08-05 | $595.00M derived: sum of 3 quarters · filed 2023-02-24 | $668.00M derived: sum of 4 quarters · filed 2023-02-24 | |
| 2022-03-31 | $113.00M 10-Q · filed 2022-05-05 | $261.00M derived: sum of 2 quarters · filed 2023-02-24 | $334.00M derived: sum of 3 quarters · filed 2023-02-24 | $494.00M derived: sum of 4 quarters · filed 2023-02-24 | |
| 2021-12-31 | $148.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $221.00M derived: sum of 2 quarters · filed 2023-02-24 | $381.00M derived: sum of 3 quarters · filed 2023-02-24 | $608.00M 10-K · filed 2023-02-24 | |
| 2021-09-30 | $73.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $233.00M derived: sum of 2 quarters · filed 2021-11-05 | $460.00M 10-Q · filed 2021-11-05 | $607.00M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2021-06-30 | $160.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $387.00M 10-Q · filed 2021-08-09 | $534.00M derived: sum of 3 quarters · filed 2022-02-25 | $675.00M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2021-03-31 | $227.00M 10-Q · filed 2021-05-05 | $374.00M derived: sum of 2 quarters · filed 2022-02-25 | $515.00M derived: sum of 3 quarters · filed 2022-02-25 | $716.00M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2020-12-31 | $147.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $288.00M derived: sum of 2 quarters · filed 2022-02-25 | $489.00M derived: sum of 3 quarters · filed 2022-02-25 | $779.00M 10-K · filed 2022-02-25 | $809.00M 10-K · filed 2021-02-25 |
| 2020-09-30 | $141.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $342.00M derived: sum of 2 quarters · filed 2020-11-05 | $632.00M 10-Q · filed 2020-11-05 | $737.00M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2020-06-30 | $201.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $491.00M 10-Q · filed 2020-08-05 | $596.00M derived: sum of 3 quarters · filed 2021-02-25 | $749.00M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2020-03-31 | $290.00M 10-Q · filed 2020-05-06 | $395.00M derived: sum of 2 quarters · filed 2021-02-25 | $548.00M derived: sum of 3 quarters · filed 2021-02-25 | $650.00M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-12-31 | $105.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $258.00M derived: sum of 2 quarters · filed 2021-02-25 | $360.00M derived: sum of 3 quarters · filed 2021-02-25 | $461.00M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $153.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $255.00M derived: sum of 2 quarters · filed 2019-11-05 | $356.00M 10-Q · filed 2019-11-05 | $538.00M derived: sum of 4 quarters · filed 2020-02-26 | |
| 2019-06-30 | $102.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $203.00M 10-Q · filed 2019-08-06 | $385.00M derived: sum of 3 quarters · filed 2020-02-26 | $585.00M derived: sum of 4 quarters · filed 2020-02-26 | |
| 2019-03-31 | $101.00M 10-Q · filed 2019-05-08 | $283.00M derived: sum of 2 quarters · filed 2020-02-26 | $483.00M derived: sum of 3 quarters · filed 2020-02-26 | $785.00M derived: sum of 4 quarters · filed 2020-02-26 | |
| 2018-12-31 | $182.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $382.00M derived: sum of 2 quarters · filed 2020-02-26 | $684.00M derived: sum of 3 quarters · filed 2020-02-26 | $887.00M 10-K · filed 2020-02-26 | |
| 2018-09-30 | $200.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $502.00M derived: sum of 2 quarters · filed 2018-11-06 | $705.00M 10-Q · filed 2018-11-06 | $864.00M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2018-06-30 | $302.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $505.00M 10-Q · filed 2018-08-07 | $664.00M derived: sum of 3 quarters · filed 2019-02-27 | $826.00M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2018-03-31 | $203.00M 10-Q · filed 2018-05-08 | $362.00M derived: sum of 2 quarters · filed 2019-02-27 | $524.00M derived: sum of 3 quarters · filed 2019-02-27 | $704.00M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-12-31 | $159.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $321.00M derived: sum of 2 quarters · filed 2019-02-27 | $501.00M derived: sum of 3 quarters · filed 2019-02-27 | $722.00M 10-K · filed 2019-02-27 | |
| 2017-09-30 | $162.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $342.00M derived: sum of 2 quarters · filed 2017-11-07 | $563.00M 10-Q · filed 2017-11-07 | $872.00M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2017-06-30 | $180.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $401.00M 10-Q · filed 2017-08-08 | $710.00M derived: sum of 3 quarters · filed 2018-02-27 | $850.00M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2017-03-31 | $221.00M 10-Q · filed 2017-05-09 | $530.00M derived: sum of 2 quarters · filed 2018-02-27 | $670.00M derived: sum of 3 quarters · filed 2018-02-27 | $807.00M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-12-31 | $309.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $449.00M derived: sum of 2 quarters · filed 2018-02-27 | $586.00M derived: sum of 3 quarters · filed 2018-02-27 | $760.00M 10-K · filed 2018-02-27 | |
| 2016-09-30 | $140.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $277.00M derived: sum of 2 quarters · filed 2016-11-07 | $451.00M 10-Q · filed 2016-11-07 | ||
| 2016-06-30 | $137.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $311.00M 10-Q · filed 2016-08-08 | |||
| 2016-03-31 | $174.00M 10-Q · filed 2016-05-09 | ||||
| 2015-12-31 | $1.08B 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |